Strata Skin Sciences, Inc. (SSKN) Financial Statements (2024 and earlier)

Company Profile

Business Address 5 WALNUT GROVE DRIVE
HORSHAM, PA 19044
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,0342,8255,4347,45410,03610,923
Cash and cash equivalents9,0342,8255,4347,45410,03610,923
Restricted cash and investments1,3611,3611,3611,361  
Receivables4,4013,9404,4713,6552,9892,972
Inventory, net of allowances, customer advances and progress billings5,9215,6955,5475,6624,9074,758
Inventory5,9215,6955,5475,6624,9074,758
Other undisclosed current assets528691691621696393
Total current assets:21,24514,51217,50418,75318,62819,046
Noncurrent Assets
Operating lease, right-of-use asset807870975836457549
Property, plant and equipment8,3198,1827,4986,5666,6856,921
Intangible assets, net (including goodwill)24,76225,47726,19726,91327,63228,371
Goodwill8,8038,8038,8038,8038,8038,803
Intangible assets, net (excluding goodwill)15,95916,67417,39418,11018,82919,568
Other noncurrent assets718298167185200
Total noncurrent assets:33,95934,61134,76834,48234,95936,041
TOTAL ASSETS:55,20449,12352,27253,23553,58755,087
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,6119,6489,98015,56515,66910,509
Taxes payable3,7423,739
Employee-related liabilities1,3791,545
Accounts payable3,8803,0993,4254,3694,2413,970
Accrued liabilities6,7316,5496,5556,0756,1446,539
Deferred revenue2,4362,5482,7782,9683,2533,121
Other undisclosed current liabilities1,073862668(4,375)(4,560)789
Total current liabilities:14,12013,05813,42614,15814,36214,419
Noncurrent Liabilities
Long-term debt and lease obligation14,9877,5177,4768,1097,6847,680
Long-term debt, excluding current maturities14,9877,5177,4767,4357,3957,356
Liabilities, other than long-term debt1,2891,1011,187491543310
Accounts payable and accrued liabilities1067771  33
Deferred revenue49022920022527711
Deferred income tax liabilities306306306266266266
Operating lease, liability387489610674289324
Other undisclosed noncurrent liabilities7,8998,1268,3528,6778,6588,898
Total noncurrent liabilities:24,17516,74417,01517,27716,88516,888
Total liabilities:38,29529,80230,44131,43531,24731,307
Equity
Equity, attributable to parent16,90919,32121,83121,80022,34023,780
Common stock353535353535
Additional paid in capital250,085249,349249,024248,833248,378247,926
Accumulated deficit(233,211)(230,063)(227,228)(227,068)(226,073)(224,181)
Total equity:16,90919,32121,83121,80022,34023,780
TOTAL LIABILITIES AND EQUITY:55,20449,12352,27253,23553,58755,087

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues8,2507,56710,6029,4139,1057,041
Cost of revenue(3,932)(3,179)(3,754)(3,614)(4,112)(2,913)
Gross profit:4,3184,3886,8485,7994,9934,128
Operating expenses(6,280)(6,974)(6,714)(6,585)(6,687)(6,431)
Operating income (loss):(1,962)(2,586)134(786)(1,694)(2,303)
Nonoperating expense(1,186)(249)(231)(209)(198)(199)
Investment income, nonoperating2137443510 
Interest and debt expense(909)(286)(275)(244)(208)(199)
Loss from continuing operations before equity method investments, income taxes:(4,057)(3,121)(372)(1,239)(2,100)(2,701)
Other undisclosed income from continuing operations before income taxes   275244208199
Loss from continuing operations before income taxes:(4,057)(3,121)(97)(995)(1,892)(2,502)
Other undisclosed loss from continuing operations   (63)   
Loss from continuing operations:(4,057)(3,121)(160)(995)(1,892)(2,502)
Loss before gain (loss) on sale of properties:(995)(1,892)(2,502)
Net loss:(4,057)(3,121)(160)(995)(1,892)(2,502)
Other undisclosed net income attributable to parent909286    
Net loss available to common stockholders, diluted:(3,148)(2,835)(160)(995)(1,892)(2,502)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(4,057)(3,121)(160)(995)(1,892)(2,502)
Comprehensive loss, net of tax, attributable to parent:(4,057)(3,121)(160)(995)(1,892)(2,502)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: